RBT

Renibus Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the prevention and treatment of cardio-renal diseases. The company's lead program, RBT-1, is a first-in-class small molecule currently in Phase 3 clinical trials designed to reduce post-operative complications, such as acute kidney injury and atrial fibrillation, following cardiothoracic surgery. Renibus also maintains a pipeline of other organ-protective agents, including RBT-2 for chronic kidney disease and RBT-3 for the prevention of cisplatin-induced nephrotoxicity. By focusing on preconditioning the body's natural defense mechanisms, Renibus aims to significantly improve outcomes for patients undergoing major surgical procedures or facing toxic drug exposures.